Brown Kate G, Chen Carina Y, Dong Deanna, Lake Kimberly J, Butelman Eduardo R
Laboratory on the Biology of Addictive Diseases, The Rockefeller University, New York, NY, United States.
Front Psychiatry. 2022 Jul 7;13:947603. doi: 10.3389/fpsyt.2022.947603. eCollection 2022.
Overdoses caused by synthetic mu-opioid receptor (MOR) agonists such as fentanyl are causing increasing mortality in the United States. The COVID-19 pandemic continues to have complex effects on public health, including opioid use disorders (OUD). It is unclear whether recent increases in mortality caused by synthetic opioids have reached a plateau (i.e., a stable period), after the onset of the COVID-19 pandemic.
This study examined provisional overdose mortality data from the Centers for Disease Control and Prevention, for synthetic opioids excluding methadone (code T40.4; monthly data available from 39 States, plus New York City and Washington DC), for June 2019-November 2021. Data were first examined as crude mortality rates. The presence of a maximum plateau was analyzed for the last 4 months of available data. For authorities in which a plateau in mortality was detected, sigmoidal Boltzmann equations were used to model parameters of this phenomenon (e.g., level of the plateau).
At the end of the study period, all but one authority (New Hampshire) reported increases in mortality rates for synthetic opioids, compared to the baseline month of June 2019 (range: 111-745% of baseline). A plateau was observed over the last 4 months of the study period (Aug 2021-Nov 2021) in 29 of the authorities. Ten other authorities had not reached a stable plateau at the end of the study period. For the authorities where a plateau was detected, a sigmoidal Boltzmann model revealed a fitted maximum of 262% rise in mortality over the study period, from the baseline month. The midpoint in the rise in mortality was fitted in September 2020. After separation of data into census regions, the highest plateau was observed in the West region, followed by South, Midwest, and Northeast (fitted plateau values were 409, 262, 204, and 149% of baseline, respectively).
There were increases in overdose mortality due to synthetic opioids across most states, ranging considerably in magnitude. A plateau in overdose mortality was detected at the end of the study period in most of these authorities. The reasons for these plateaus should be explored, in order to develop optimized public health interventions.
在美国,由芬太尼等合成μ-阿片受体(MOR)激动剂导致的过量用药造成的死亡率不断上升。2019冠状病毒病(COVID-19)大流行继续对公共卫生产生复杂影响,包括阿片类药物使用障碍(OUD)。目前尚不清楚在COVID-19大流行开始后,由合成阿片类药物导致的近期死亡率上升是否已达到平稳期(即稳定期)。
本研究调查了美国疾病控制与预防中心提供的2019年6月至2021年11月期间,除美沙酮外的合成阿片类药物(代码T40.4;可从39个州以及纽约市和华盛顿特区获取月度数据)的临时过量用药死亡率数据。数据首先作为粗死亡率进行检查。对可用数据的最后4个月分析是否存在最高平稳期。对于检测到死亡率平稳的地区,使用S形玻尔兹曼方程对这一现象的参数(如平稳期水平)进行建模。
在研究期结束时,除一个地区(新罕布什尔州)外,所有地区报告的合成阿片类药物死亡率均高于2019年6月的基线月(范围为基线的111%-745%)。在29个地区的研究期最后4个月(2021年8月至2021年11月)观察到了平稳期。其他10个地区在研究期结束时尚未达到稳定的平稳期。对于检测到平稳期的地区,S形玻尔兹曼模型显示,在整个研究期内,死亡率较基线月最高上升了262%。死亡率上升的中点拟合为2020年9月。将数据按人口普查区域划分后,西部地区观察到的平稳期最高,其次是南部、中西部和东北部(拟合的平稳期值分别为基线的409%、262%、204%和149%)。
大多数州因合成阿片类药物导致的过量用药死亡率均有所上升,幅度差异很大。在大多数这些地区的研究期结束时检测到了过量用药死亡率的平稳期。应探究这些平稳期的原因,以便制定优化的公共卫生干预措施。